.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
Dow
Cantor Fitzgerald
Farmers Insurance
Chubb
Harvard Business School
Deloitte
US Department of Justice
AstraZeneca
Baxter

Generated: June 25, 2017

DrugPatentWatch Database Preview

Galantamine hydrobromide - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for galantamine hydrobromide and what is the scope of galantamine hydrobromide patent protection?

Galantamine hydrobromide
is the generic ingredient in three branded drugs marketed by Mylan, Yabao Pharm, Barr, West-ward Pharms Int, Janssen Pharms, Watson Labs, Aurobindo Pharma Ltd, Sun Pharma Global, Apotex Inc, Impax Labs, Actavis Elizabeth, Teva Pharms, Sandoz, Dr Reddys Labs Ltd, and Zydus Pharms Usa Inc, and is included in twenty-two NDAs. There are four patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Galantamine hydrobromide has eighty-four patent family members in thirty-five countries.

There are fifteen drug master file entries for galantamine hydrobromide. Twenty suppliers are listed for this compound. There are three tentative approvals for this compound.

Summary for Generic Name: galantamine hydrobromide

Tradenames:3
Patents:4
Applicants:15
NDAs:22
Drug Master File Entries: see list15
Suppliers / Packagers: see list20
Bulk Api Vendors: see list53
Clinical Trials: see list146
Patent Applications: see list538
Therapeutic Class:Antidementia Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:galantamine hydrobromide at DailyMed

Pharmacology for Ingredient: galantamine hydrobromide

Tentative approvals for GALANTAMINE HYDROBROMIDE

Applicant Application No. Strength Dosage Form
► Subscribe► Subscribe4MGTABLET; ORAL
► Subscribe► Subscribe12MGTABLET; ORAL
► Subscribe► Subscribe8MGTABLET; ORAL
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Zydus Pharms Usa Inc
GALANTAMINE HYDROBROMIDE
galantamine hydrobromide
TABLET;ORAL078898-001Feb 17, 2011ABRXNoNo► Subscribe► Subscribe
Teva Pharms
GALANTAMINE HYDROBROMIDE
galantamine hydrobromide
TABLET;ORAL077587-003Jul 9, 2009ABRXNoNo► Subscribe► Subscribe
Janssen Pharms
RAZADYNE ER
galantamine hydrobromide
CAPSULE, EXTENDED RELEASE;ORAL021615-001Apr 1, 2005ABRXYesYes7,160,559► SubscribeY ► Subscribe
Impax Labs
GALANTAMINE HYDROBROMIDE
galantamine hydrobromide
CAPSULE, EXTENDED RELEASE;ORAL078484-003May 27, 2009DISCNNoNo► Subscribe► Subscribe
Janssen Pharms
RAZADYNE ER
galantamine hydrobromide
CAPSULE, EXTENDED RELEASE;ORAL021615-003Apr 1, 2005ABRXYesNo7,160,559► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: galantamine hydrobromide

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Janssen Pharms
RAZADYNE
galantamine hydrobromide
SOLUTION;ORAL021224-001Jun 22, 20014,663,318► Subscribe
Janssen Pharms
RAZADYNE
galantamine hydrobromide
TABLET;ORAL021169-001Feb 28, 20016,099,863► Subscribe
Janssen Pharms
RAZADYNE
galantamine hydrobromide
TABLET;ORAL021169-001Feb 28, 20016,358,527► Subscribe
Janssen Pharms
RAZADYNE ER
galantamine hydrobromide
CAPSULE, EXTENDED RELEASE;ORAL021615-001Apr 1, 20054,663,318► Subscribe
Janssen Pharms
RAZADYNE
galantamine hydrobromide
TABLET;ORAL021169-001Feb 28, 20014,663,318► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: galantamine hydrobromide

Country Document Number Estimated Expiration
Turkey9802592► Subscribe
Eurasian Patent Organization001193► Subscribe
Poland189329► Subscribe
Norway20012857► Subscribe
European Patent Office0915701► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: GALANTAMINE HYDROBROMIDE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00140Netherlands► SubscribePRODUCT NAME: GALANTAMINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZUURADDITIEZOUT, IN HET BIJZONDER GALANTAMINE HYDROBROMIDE; NAT. REGISTRATION NO/DATE: RVG 29073 - RVG 29076 20030702; FIRST REGISTRATION: SE 15561 - 15565 20000225
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Army
Cantor Fitzgerald
Dow
Chubb
Accenture
Julphar
Deloitte
AstraZeneca
Novartis
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot